Amid an environment of higher-than-expected inflation, rate hikes and a slowing global economy, health care’s defensive nature may offer attractive characteristics. In our view, depressed valuations and accelerating innovation make biotech particularly appealing, while other areas of healthcare could continue to shine near term.

Watch here as Portfolio Manager Andy Acker explains why the sector could offer both defence against market volatility and opportunities for long-term gains.